133 related articles for article (PubMed ID: 25693785)
1. Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist.
Suzuki R; Nozawa D; Futamura A; Nishikawa-Shimono R; Abe M; Hattori N; Ohta H; Araki Y; Kambe D; Ohmichi M; Tokura S; Aoki T; Ohtake N; Kawamoto H
Bioorg Med Chem; 2015 Mar; 23(6):1260-75. PubMed ID: 25693785
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
[TBL] [Abstract][Full Text] [Related]
3. Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide.
Futamura A; Nozawa D; Araki Y; Tamura Y; Tokura S; Kawamoto H; Tokumaru Y; Kakihara S; Aoki T; Ohtake N
Bioorg Med Chem; 2017 Oct; 25(20):5203-5215. PubMed ID: 28807572
[TBL] [Abstract][Full Text] [Related]
4. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
5. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia.
Futamura A; Suzuki R; Tamura Y; Kawamoto H; Ohmichi M; Hino N; Tokumaru Y; Kirinuki S; Hiyoshi T; Aoki T; Kambe D; Nozawa D
Bioorg Med Chem; 2020 Jul; 28(13):115489. PubMed ID: 32482533
[TBL] [Abstract][Full Text] [Related]
6. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
[TBL] [Abstract][Full Text] [Related]
7. From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs.
Brotschi C; Bolli MH; Gatfield J; Heidmann B; Jenck F; Roch C; Sifferlen T; Treiber A; Williams JT; Boss C
ChemMedChem; 2020 Mar; 15(5):430-448. PubMed ID: 31945272
[TBL] [Abstract][Full Text] [Related]
8. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
Brotschi C; Roch C; Gatfield J; Treiber A; Williams JT; Sifferlen T; Heidmann B; Jenck F; Bolli MH; Boss C
ChemMedChem; 2019 Jul; 14(13):1257-1270. PubMed ID: 31066976
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators.
Iino T; Tsukahara D; Kamata K; Sasaki K; Ohyama S; Hosaka H; Hasegawa T; Chiba M; Nagata Y; Eiki J; Nishimura T
Bioorg Med Chem; 2009 Apr; 17(7):2733-43. PubMed ID: 19282189
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878.
Maehara S; Yuge N; Higashi C; Ota T; Furukawa J; Takeuchi T
Neuropsychopharmacol Rep; 2020 Jun; 40(2):182-189. PubMed ID: 32337858
[TBL] [Abstract][Full Text] [Related]
11. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
Bonaventure P; Shelton J; Yun S; Nepomuceno D; Sutton S; Aluisio L; Fraser I; Lord B; Shoblock J; Welty N; Chaplan SR; Aguilar Z; Halter R; Ndifor A; Koudriakova T; Rizzolio M; Letavic M; Carruthers NI; Lovenberg T; Dugovic C
J Pharmacol Exp Ther; 2015 Sep; 354(3):471-82. PubMed ID: 26177655
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
[TBL] [Abstract][Full Text] [Related]
13. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
Roecker AJ; Reger TS; Mattern MC; Mercer SP; Bergman JM; Schreier JD; Cube RV; Cox CD; Li D; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2014 Oct; 24(20):4884-90. PubMed ID: 25248679
[TBL] [Abstract][Full Text] [Related]
14. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.
Sifferlen T; Boller A; Chardonneau A; Cottreel E; Gatfield J; Treiber A; Roch C; Jenck F; Aissaoui H; Williams JT; Brotschi C; Heidmann B; Siegrist R; Boss C
Bioorg Med Chem Lett; 2015 May; 25(9):1884-91. PubMed ID: 25838147
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach.
Heidmann B; Gatfield J; Roch C; Treiber A; Tortoioli S; Brotschi C; Williams JT; Bolli MH; Abele S; Sifferlen T; Jenck F; Boss C
ChemMedChem; 2016 Oct; 11(19):2132-2146. PubMed ID: 27390287
[TBL] [Abstract][Full Text] [Related]
16. Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist.
Yoshida Y; Naoe Y; Terauchi T; Ozaki F; Doko T; Takemura A; Tanaka T; Sorimachi K; Beuckmann CT; Suzuki M; Ueno T; Ozaki S; Yonaga M
J Med Chem; 2015 Jun; 58(11):4648-64. PubMed ID: 25953512
[TBL] [Abstract][Full Text] [Related]
17. 6,7-Dimethoxy-2-{2-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolines as superior reversal agents for P-glycoprotein-mediated multidrug resistance.
Liu B; Qiu Q; Zhao T; Jiao L; Li Y; Huang W; Qian H
ChemMedChem; 2015 Feb; 10(2):336-44. PubMed ID: 25470220
[TBL] [Abstract][Full Text] [Related]
18. The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468.
Treiber A; de Kanter R; Roch C; Gatfield J; Boss C; von Raumer M; Schindelholz B; Muehlan C; van Gerven J; Jenck F
J Pharmacol Exp Ther; 2017 Sep; 362(3):489-503. PubMed ID: 28663311
[TBL] [Abstract][Full Text] [Related]
19. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
Raheem IT; Breslin MJ; Bruno J; Cabalu TD; Cooke A; Cox CD; Cui D; Garson S; Gotter AL; Fox SV; Harrell CM; Kuduk SD; Lemaire W; Prueksaritanont T; Renger JJ; Stump C; Tannenbaum PL; Williams PD; Winrow CJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Feb; 25(3):444-50. PubMed ID: 25577040
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).
Suzuki G; Kimura T; Satow A; Kaneko N; Fukuda J; Hikichi H; Sakai N; Maehara S; Kawagoe-Takaki H; Hata M; Azuma T; Ito S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2007 Jun; 321(3):1144-53. PubMed ID: 17360958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
